A growing portfolio of RNA-based cancer diagnostics

Many tumor types share common molecular subtypes, allowing us to leverage these characteristic subtypes to identify candidate responder populations across numerous indications. We work with nearly any mechanism of action and have the capability to build de novo gene signatures for biopharmaceutical partners.

By applying cancer subtyping with the rT(I)ME Explorer platform to specific types of cancer and target biology, our diagnostics portfolio is actively engaged in deriving drug-predictive response signatures and companion diagnostics for targeted therapies and immunotherapies.